Insilico Medicine and Bora Pharmaceuticals Form AI Drug Discovery Pact

The collaboration unites Insilico’s Pharma.AI platform—which manages target identification and generative chemistry—with Bora’s global expertise in drug development, quality systems, and supply chain execution. By bridging the gap between digital discovery and physical production, the companies intend to reduce the time required to bring novel medicines to patients. Insilico currently reports that its AI-driven approach can identify preclinical candidates in 12 to 18 months, significantly faster than the industry standard of 2.5 to 4 years.

Beyond specific drug development, the alliance aims to digitize Bora’s internal operations. Insilico plans to provide comprehensive R&D strategies and training to enhance AI literacy across Bora’s workforce. This includes applying machine learning to manufacturing readiness, process optimization, and corporate supply chain management. Bobby Sheng, founder and CEO of Bora Pharmaceuticals, noted that the move marks the company’s evolution from a service provider into a broader drug innovation ecosystem. Dr. Alex Zhavoronkov, co-CEO of Insilico, emphasized that the partnership serves as a scalable model for demonstrating the efficiency of AI-discovered medicines across the Asia-Pacific region.